HENDERSON, Nev., November 07, 2024--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback